Pernix Therapeutics (PTX) Misses Q1 EPS by 36c, Withdraws Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update
May 5, 2016 8:01 AM EDTPernix Prescriptions DirectTM Achieves Increased Penetration
MORRISTOWN, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) (Pernix or the Company), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2016.
First Quarter 2016 Financial Highlights:
Net Revenue decreased 4% year-over-year to $32.5 million, principally due to lower sales volumes and higher managed care rebates for Treximet® and Silenor®Gross Margin of 65% was comparable to the first quarter 2015Adjusted EBITDA... More